Literature DB >> 6366820

A comparative study of zopiclone and flunitrazepam in insomniacs seen by general practitioners.

E Wickstrøm, S E Barbo, J F Dreyfus, D Jerkø, R Kleiven, R Slåttbrekk, J N Stray Tønnesen.   

Abstract

A double-blind crossover trial was conducted in 42 outpatients of either sex in order to obtain information on the properties of 7.5 mg of zopiclone in a general practice setting compared with 2 mg of flunitrazepam. Each patient went through two periods of treatment, each period lasting 10 days. A comparison of the effect of the drugs showed a significant difference with regard to effectiveness and sleep latency favoring flunitrazepam. When patient's preferences were analyzed there was a highly significant difference favoring flunitrazepam both for effectiveness and tolerance. The side effects from both drugs were generally mild.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6366820     DOI: 10.1159/000137923

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  6 in total

1.  Effective stress management.

Authors:  R France
Journal:  Occas Pap R Coll Gen Pract       Date:  1993-08

Review 2.  Rebound insomnia and newer hypnotics.

Authors:  M Lader
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Comparison of the clinical hypnotic effects of zopiclone and triazolam.

Authors:  E Autret; F Maillard; A Autret
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 4.  Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic.

Authors:  A N Wadworth; D McTavish
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

Review 5.  Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic.

Authors:  K L Goa; R C Heel
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

6.  Eszopiclone: its use in the treatment of insomnia.

Authors:  Jaime M Monti; S R Pandi-Perumal
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.